Aiolos and Eos drive distinct human TH17 functional states

Résumé fourni par la source

CD4+ T helper (TH)-17 cells play a pivotal role in mucosal immune defense and are implicated in autoimmune diseases and cancer. Although Th17 cell plasticity is well-studied in mice, the factors driving their transition between pro-inflammatory and immunomodulatory states in humans remain less understood. Our study explored the transcriptional and epigenetic landscapes of single-cell cultures of human memory TH17 cells, focusing on clones that produce either immunomodulatory IL-10 or pro-inflammatory IFNγ and IL-22. We found that IL-10+ TH17 cells exhibit a T cell exhaustion-like profile with increased CTLA-4 expression and reduced IL-2 levels, while Ikaros zinc finger (IkZF) transcription factors, Aiolos and Eos, are differentially expressed in IL-10+ and IL-22+ TH17 cells, respectively. While exogenous IL-2 promotes IL-10 production in TH17 cells, lenalidomide induces IL-2 and promotes inflammatory TH17 cells, shifting TH17 cells towards a pro-inflammatory phenotype by reducing IL-10 and increasing IL-22 and IFNγ levels. Conversely, upregulation of Eos enhanced pro-inflammatory cytokine production. These findings highlight the crucial role of IkZF transcription factors in regulating human TH17 cell functions. Moreover, single-cell RNA sequencing of PBMCs from lenalidomide-treated patients confirmed an enrichment of inflammatory signatures, including interferon and IL-2/STAT5 pathways in TH17 cells. The ability to modulate this axis through targeted interventions, such as lenalidomide-induced Aiolos degradation or enforced Eos expression, presents new therapeutic opportunities for managing TH17 cell states in cancer and autoimmune diseases.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.